Zobrazeno 1 - 10
of 156
pro vyhledávání: ''
Autor:
Sepideh Azarianpour, Germán Corredor, Kaustav Bera, Patrick Leo, Pingfu Fu, Paula Toro, Amy Joehlin-Price, Mojgan Mokhtari, Haider Mahdi, Anant Madabhushi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
BackgroundWe present a computational approach (ArcTIL) for quantitative characterization of the architecture of tumor-infiltrating lymphocytes (TILs) and their interplay with cancer cells from digitized H&E-stained histology whole slide images and ev
Autor:
George R Blumenschein, Siddhartha Devarakonda, Melissa Johnson, Victor Moreno, Justin Gainor, Martin J Edelman, John V Heymach, Ramaswamy Govindan, Carlos Bachier, Bernard Doger de Spéville, Matthew J Frigault, Anthony J Olszanski, Vincent K Lam, Natalie Hyland, Jean-Marc Navenot, Svetlana Fayngerts, Zohar Wolchinsky, Robyn Broad, Dzmitry Batrakou, Melissa M Pentony, Joseph P Sanderson, Andrew Gerry, Diane Marks, Jane Bai, Tom Holdich, Elliot Norry, Paula M Fracasso
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
BackgroundADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T cells (ADP-A2M10) are genetically engineered autologous T cells that express a high-affinity melanoma-associated antigen A10 (MAGE-A10)-specific T-cell receptor (TCR) targeting
Autor:
Lingfang Xia, Jin Peng, Ge Lou, Mei Pan, Qi Zhou, Wenjing Hu, Huirong Shi, Li Wang, Yunong Gao, Jianqing Zhu, Yu Zhang, Rong Sun, Xianfeng Zhou, Quanren Wang, Xiaohua Wu
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
BackgroundCombination treatments with immune-checkpoint inhibitor and antiangiogenic therapy have the potential for synergistic activity through modulation of the microenvironment and represent a notable therapeutic strategy in recurrent ovarian canc
Autor:
Pashtoon Murtaza Kasi, Griffin Budde, Michael Krainock, Vasily N Aushev, Allyson Koyen Malashevich, Meenakshi Malhotra, Perry Olshan, Paul R Billings, Alexey Aleshin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Immune checkpoint inhibitors have shown great promise in treating patients with mismatch repair deficient/microsatellite instability high (dMMR/MSI-H) colorectal cancer (CRC). Although single-agent pembrolizumab has been approved for first-line treat
Autor:
Ying Jing, Xue Chen, Kunyan Li, Yaoming Liu, Zhao Zhang, Yiqing Chen, Yuan Liu, Yushu Wang, Steven H Lin, Lixia Diao, Jing Wang, Yanyan Lou, Douglas B Johnson, Xiang Chen, Hong Liu, Leng Han
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundTo determine whether antibiotic treatment is a risk factor for immune-related adverse events (irAEs) across different patients with cancer receiving anti-PD-1/PD-L1 therapies.MethodsThe retrospective analysis includes clinical information f
Autor:
Cristescu, Razvan, Aurora-Garg, Deepti, Albright, Andrew, Xu, Lei, Liu, Xiao Qiao, Loboda, Andrey, Lang, Lixin, Jin, Fan, Rubin, Eric H, Snyder, Alexandra, Lunceford, Jared
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundSeveral studies have evaluated the relationship between tumor mutational burden (TMB) and outcomes of immune checkpoint inhibitors. In the phase II KEYNOTE-158 study of pembrolizumab monotherapy for previously treated recurrent or metastati
Autor:
Valentín Ortiz-Maldonado, Susana Rives, Marta Español-Rego, Anna Alonso-Saladrigues, Mercedes Montoro, Laura Magnano, Eva Giné, Mariona Pascal, Marina Díaz-Beyá, Maria Castella, Albert Català, Anna Faura, Luis Gerardo Rodríguez-Lobato, Aina Oliver-Caldes, Alexandra Martínez-Roca, Montserrat Rovira, E Azucena González-Navarro, Juan Ramón Ortega, Joan Cid, Miquel Lozano, Enric Garcia-Rey, Sara Fernández, Pedro Castro, Iolanda Jordan, Neus Villamor, Marta Aymerich, Montserrat Torrebadell, Àngela Deyà, Carlos Fernández de Larrea, Daniel Benitez-Ribas, Esteve Trias, Sara Varea, Gonzalo Calvo, Jordi Esteve, Alvaro Urbano-Ispizua, Manel Juan, Julio Delgado
Publikováno v:
Journal for Immunotherapy of Cancer
The prognosis of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains poor, particularly for those relapsing after allogeneic hema-topoietic cell transplantation (alloHCT). Novel agents such as inotuzumab ozogamicin or b
Autor:
Jingfei Ma, Asif Rashid, Subramanya Sandesh, Anuj Verma, Jia Sun, Ignacio I. Wistuba, Jason Stafford, Aliya Qayyum, Ken Pin Hwang, Rony Avritscher, Richard L. Ehman, Ahmed Kaseb, Manal M. Hassan, Roberto Carmagnani Pestana, Hesham M. Amin, Dipen M. Maru
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-6 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Currently, there are no imaging predictors of immunotherapy outcome in hepatocellular carcinoma (HCC). The study aim was to determine if stiffness changes measured by magnetic resonance elastography (MRE) can be a predictor of immunotherap
Autor:
Marieke J. Krimphove, Luis A. Kluth, David F. Friedlander, Praful Ravi, Adam S. Kibel, Toni K. Choueiri, Patrick A. Ott, Karl H. Tully, Quoc-Dien Trinh, Maya Marchese, Stuart R. Lipsitz, Kerry L. Kilbridge
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background The introduction of immune checkpoint inhibitors has led to a survival benefit in patients with advanced melanoma; however data on the adoption of immunotherapy in the community are scarce. Methods Using the National Cancer Database, we id
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Immune-checkpoint inhibitors (ICIs) emerged as a novel class of drugs for the treatment of a broad spectrum of malignancies. ICIs can produce durable antitumor responses but they are also associated with immune-related adverse events (irAE